Restricted cubic spline analysis of treatment duration before tocilizumab withdrawal and relapse risk in rheumatoid arthritis
Therapeutic Advances in Musculoskeletal Disease
Published online on July 04, 2026
Abstract
Therapeutic Advances in Musculoskeletal Disease, Volume 18, January-December 2026.
Background:Tocilizumab (TCZ), an interleukin-6 receptor inhibitor, is effective for moderate to severe rheumatoid arthritis (RA). However, maintaining remission after TCZ withdrawal remains challenging, and the treatment duration required before ...
Background:Tocilizumab (TCZ), an interleukin-6 receptor inhibitor, is effective for moderate to severe rheumatoid arthritis (RA). However, maintaining remission after TCZ withdrawal remains challenging, and the treatment duration required before ...